Dynavax Technologies Corp- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Dynavax Technologies Corp 公司

Dynavax Technologies Corporation 是一家商业阶段生物制药公司，致力于开发和商业化疫苗。该公司的产品包括 HEPLISAV-B 乙肝疫苗和 CpG 1018。其 HEPLISAV-B（重组）（佐剂）用于预防 18 岁及以上成人中所有已知乙肝病毒亚型引起的感染。HEPLISAV-B 是一种两剂成人乙肝疫苗。该公司还生产和销售 CpG 1018 佐剂，即 HEPLISAV-B 中使用的佐剂。该公司还致力于开发利用 CpG 1018 佐剂的多项目临床管线，以开发针对未满足医疗需求的适应症的改良疫苗。其管线项目包括正在开发的带状疱疹、破伤风、白喉和百日咳 (Tdap) 和鼠疫的候选疫苗。其带状疱疹疫苗项目 Z-1018 是一种正在开发的用于预防 50 岁成人带状疱疹的试验性候选疫苗及以上。

Dynavax Technologies Corp简介



公司代码DVAX

公司名称Dynavax Technologies Corp

上市日期Feb 19, 2004

CEOMr. Ryan Spencer

员工数量405

证券类型Ordinary Share

年结日Feb 19

公司地址2100 Powell Street

城市EMERYVILLE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编94608

电话15108485100

网址https://www.dynavax.com/

公司代码DVAX

上市日期Feb 19, 2004

CEOMr. Ryan Spencer

Dynavax Technologies Corp公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

Dr. Peter R. Paradiso, Ph.D.

Independent Director

24.83K

+30.19%

Dr. Daniel L. (Dan) Kisner, M.D.

Independent Director

23.33K

+32.77%

Mr. Brent MacGregor

Independent Director

21.83K

+35.83%

Dr. Emilio Emini

Independent Director

1.44K

--

名称

名称/职务

职务

持股

持股变动

Mr. Ryan Spencer

Chief Executive Officer, Director

277.67K

--

Dr. Robert (Rob) Janssen, M.D.

Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs

74.92K

--

Mr. David F. Novack

Chief Operating Officer, Senior Vice President

56.05K

+33.36%

Mr. John L. Slebir

Senior Vice President, General Counsel

31.42K

--

Ms. Elaine D. Sun

Independent Director

29.86K

+23.89%

Ms. Kelly MacDonald, CPA

Chief Financial Officer, Senior Vice President

25.52K

--

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

业务USD

名称

营收

占比

HEPLISAV-B

91.87M

96.26%

Other revenue

3.57M

3.74%

地区USD

名称

营收

占比

US

93.57M

98.04%

Non-US

1.88M

1.96%

业务

地区

业务USD

名称

营收

占比

HEPLISAV-B

91.87M

96.26%

Other revenue

3.57M

3.74%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.47%

Deep Track Capital LP

13.41%

The Vanguard Group, Inc.

7.17%

State Street Investment Management (US)

5.45%

Chicago Capital, LLC

3.67%

其他

56.82%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

13.47%

Deep Track Capital LP

13.41%

The Vanguard Group, Inc.

7.17%

State Street Investment Management (US)

5.45%

Chicago Capital, LLC

3.67%

其他

56.82%

股东类型

持股股东

占比

Investment Advisor

38.11%

Hedge Fund

31.52%

Investment Advisor/Hedge Fund

21.01%

Research Firm

5.09%

Pension Fund

1.26%

Individual Investor

0.61%

Bank and Trust

0.48%

Private Equity

0.04%

Insurance Company

0.03%

其他

1.87%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

552

114.03M

97.24%

-27.05M

2025Q2

553

130.55M

108.79%

-14.73M

2025Q1

575

132.57M

110.30%

-15.70M

2024Q4

565

133.92M

107.04%

-18.98M

2024Q3

561

132.88M

101.45%

-18.82M

2024Q2

547

135.21M

103.33%

-14.69M

2024Q1

545

136.49M

104.51%

-4.07M

2023Q4

529

128.50M

99.42%

-9.47M

2023Q3

515

128.65M

99.89%

-9.14M

2023Q2

503

129.32M

100.65%

-12.27M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

15.80M

13.47%

-2.85M

-15.27%

Jun 30, 2025

Deep Track Capital LP

15.73M

13.41%

-2.07M

-11.61%

Aug 22, 2025

The Vanguard Group, Inc.

8.40M

7.17%

-266.13K

-3.07%

Jun 30, 2025

State Street Investment Management (US)

6.40M

5.45%

-394.51K

-5.81%

Jun 30, 2025

Chicago Capital, LLC

5.23M

4.46%

-116.66K

-2.18%

Jun 30, 2025

Two Sigma Investments, LP

3.80M

3.24%

+1.53M

+67.74%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.64M

3.11%

-365.20K

-9.11%

Jun 30, 2025

Renaissance Technologies LLC

2.89M

2.46%

+181.00K

+6.69%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.69M

2.29%

-377.05K

-12.30%

Jun 30, 2025

William Blair & Company, L.L.C. (Research)

2.28M

1.94%

+6.94K

+0.31%

Jun 30, 2025

持股ETF



更新时间: 23 小时前

机构名称

占比

Invesco Biotechnology & Genome ETF

2.54%

Virtus LifeSci Biotech Products ETF

1.59%

ETC 6 Meridian Small Cap Equity ETF

1.15%

Invesco S&P SmallCap Health Care ETF

0.63%

SPDR S&P Biotech ETF

0.42%

Pacer US Small Cap Cash Cows Growth Leaders ETF

0.41%

ETC 6 Meridian Low Beta Equity Strategy ETF

0.41%

Themes US Small Cap Cash Flow Champions ETF

0.35%

Royce Quant Small-Cap Quality Value ETF

0.3%

Franklin Genomic Advancements ETF

0.27%

Invesco Biotechnology & Genome ETF

占比2.54%

Virtus LifeSci Biotech Products ETF

占比1.59%

ETC 6 Meridian Small Cap Equity ETF

占比1.15%

Invesco S&P SmallCap Health Care ETF

占比0.63%

SPDR S&P Biotech ETF

占比0.42%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比0.41%

ETC 6 Meridian Low Beta Equity Strategy ETF

占比0.41%

Themes US Small Cap Cash Flow Champions ETF

占比0.35%

Royce Quant Small-Cap Quality Value ETF

占比0.3%

Franklin Genomic Advancements ETF

占比0.27%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据